Long-Term Response of Equids With Pituitary Pars Intermedia Dysfunction to Treatment With Pergolide
Journal of Veterinary Internal Medicine · 2025
DOI: 10.1111/jvim.70109 ↗At a glance
Journal article in Journal of Veterinary Internal Medicine, 2025. Written by Harold C Schott and 3 co-authors. Institution: Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan, USA. Major MEDLINE topics: Pergolide, Horse Diseases, Pituitary Gland, Intermediate, Pituitary Diseases. Cited 7 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Michigan State University College of Veterinary Medicine Endowed Research Funds.
Abstract (original language)
Background
Limited data document long-term responses of equids with pituitary pars intermedia dysfunction (PPID) to pergolide treatment.
Objectives
Report clinical response, medical problems, outcome, and owner satisfaction with pergolide treatment of PPID-affected equids over 14 years. Animals Thirty client-owned equids with PPID.
Methods
After completion of an open field clinical efficacy study for Prascend® (pergolide tablets), 28 horses and two ponies were enrolled in an extended treatment study (13 receiving 2 μg/kg PO q24h and 17 receiving 4 μg/kg PO q24h). Clients were interviewed every 3 months and equids were re-evaluated after 2.5, 3, 3.5, 4.5, 5.5, 6.5, 9.5, 12.5, and 14.5 years of treatment.
Results
Five equids died and 24 were euthanized (five for chronic laminitis) during the study period (median survival time, 3.6 years; range 0.6–10.5 years). Seven of 13 equids had a dosage increase to 4 μg/kg PO q24h (maximum study dose) between 1.7 to 4.7 years of the study. After 5.5 years, owners of 13 surviving equids reported sustained clinical improvement and endocrine test results normalized in 75%. After 9.5 years of treatment, only two of six surviving equids had normal endocrine test results. Conclusions and Clinical Importance Long-term treatment of PPID-affected equids with pergolide produces clinical improvement in nearly all affected animals and normalization of endocrine test results in some cases. Furthermore, this extended treatment study determined that equids can respond favorably long-term to the initial pergolide dose, rather than needing a progressive increase in dose over time.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan, USA.
- Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
ORCID profiles: Harold C Schott
Funding
- Michigan State University College of Veterinary Medicine Endowed Research Funds
Cite
APA
Schott, H. C., Strachota, J. R., Marteniuk, J. V., & Refsal, K. R. (2025). Long-Term Response of Equids With Pituitary Pars Intermedia Dysfunction to Treatment With Pergolide. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.70109
Vancouver
Schott HC, Strachota JR, Marteniuk JV, Refsal KR. Long-Term Response of Equids With Pituitary Pars Intermedia Dysfunction to Treatment With Pergolide. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.70109
BibTeX
@article{Schott2025,
author = {Schott, Harold C and Strachota, Julie R and Marteniuk, Judith V and Refsal, Kent R},
title = {Long-Term Response of Equids With Pituitary Pars Intermedia Dysfunction to Treatment With Pergolide},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
doi = {10.1111/jvim.70109}
}
EUVIMED